BLCO Stock Drops After-Hours — Bausch + Lomb Halts Glaucoma Eye Drop Program After Trial Failure
Bausch + Lomb (BLCO) said its experimental glaucoma eye drop BL1107 failed in a mid-stage trial of 159 patients. After 28 days it did not improve visual field scores, though it lowered eye pressure and showed no new safety issues. The company halted daily-drop development and will pursue a sustained-release implant for geographic atrophy instead.
How this was made
The 30-second read
Why it matters
The company stopped BL1107 development after missing the primary endpoint (visual field score improvement), despite achieving a secondary eye-pressure reduction and no new safety concerns.
Market read
A primary clinical-trial failure is a direct repricing catalyst for BLCO, with the next potential valuation support tied to later 2026 readouts in other programs.
What to watch
Management is redirecting resources to a sustained-release implant for geographic atrophy, with trials expected to begin in 2028, which could partially offset the glaucoma setback over a longer horizon.
Background
Bausch + Lomb’s experimental glaucoma eye drop BL1107 was tested in a randomized, double-masked mid-stage study of 159 patients.
Ticker impact
Bausch + Lomb halted its glaucoma drug BL1107 after a mid-stage trial failed to improve visual field scores, sending shares down after hours.
Bearish bias for BLCO near term as investors reprice pipeline risk; downside may persist until new readouts (dry eye, ocular pain) provide offsets.
The article states the company stopped development of BL1107 after missing the primary endpoint, which is a direct, company-specific negative catalyst.
Market effects
Adds to ophthalmology drug-development risk perception, particularly for glaucoma topical therapies and trial endpoint reliability.
Primarily US small-to-mid cap biotech/healthcare sentiment via after-hours repricing.
Limited global spillover; impact is concentrated in ophthalmology pipeline investors.
Counterpoint
The drug still lowered eye pressure and safety was consistent, so investors may view the failure as a program-specific setback rather than a platform-wide issue.
Key entities
- companyBausch + Lomb
Subject of the article; halted BL1107 glaucoma program after trial failure and redirected pipeline focus.
- drug_programBL1107
Experimental topical glaucoma treatment that failed to improve visual field scores in a mid-stage trial.
- drug_programBL1332
Ocular pain program mentioned as having data readouts expected in H2 2026.
